Published in J Physiol on September 15, 2014
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension (2003) 5.63
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol (2011) 3.08
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension (2005) 2.23
Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension (2011) 1.97
Prolonged activation of the baroreflex produces sustained hypotension. Hypertension (2004) 1.86
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol (2010) 1.82
NEUROGENIC HYPERTENSION IN THE RAT. Circ Res (1964) 1.79
C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation (2007) 1.59
Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension (2007) 1.48
Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension (2006) 1.36
Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension (2009) 1.33
Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens (2012) 1.20
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens (2012) 1.19
Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation (1987) 1.12
Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol (2002) 1.10
An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg (2007) 1.02
Renal responses to chronic suppression of central sympathetic outflow. Hypertension (2012) 0.96
Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol (2013) 0.95
Management of uncontrollable hypertension with a carotid sinus stimulation device. Hypertension (2007) 0.94
Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol (2011) 0.90
Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension. Am J Physiol Heart Circ Physiol (2013) 0.89
Vasopressin and blood pressure in humans. Hypertension (2000) 0.83
The effect of carotid sinus nerve stimulation on cardiovascular dynamics in man. Angiology (1969) 0.81
Limited acute influences of electrical baroreceptor activation on insulin sensitivity and glucose delivery: a randomized, double-blind, crossover clinical study. Diabetes (2014) 0.80